Abstract

Cervical cancer remains a significant global public health issue, particularly in Low- and Middle-Income Countries (LMICs), where its burden is disproportionately high. Although there has been increasing attention from the global scientific community, governmental actions have not aligned with the ambitious targets set by the World Health Organization (WHO) for the eradication of cervical cancer by 2030. International collaborations are essential to address disparities in access to HPV vaccination and screening programs, both crucial components for scaling up prevention efforts in underserved regions. Since 2020, following the WHO’s launch of a strategy focused exclusively on the elimination of cervical cancer, new considerations have emerged, including relevant changes on screening guidelines. These developments reflect divergent perceptions and the need for updated strategies to make the 2030 targets achievable. A brief summary of the Evidence-to-decision framework that is explained on WHO’s guidelines for HPV mRNA testing in cervical cancer prevention is outlined.

Keywords:HPV; Cervical cancer; Screening